Table 3.

Data for PLCO and Mayo Clinic phase III studies.

A
AUC (95% CI)PLCO (cases = 179)PLCO: within 3 years of DX (cases = 64)PLCO: within 2 years of DX (cases = 44)
CA19-9 ≥ 550.557 (0.54–0.57)0.649 (0.60–0.69)0.697 (0.64–0.75)
THBS2 − Auto0.547 (0.48–0.59)0.536 (0.48–0.59)0.568 (0.50–0.64)
CA19-9 ≥ 55 + THBS2 − Auto0.587 (0.51–0.63)0.640 (0.59–0.72)0.713 (0.62–0.78)
B
AUC (95% CI)Mayo (cases = 37)Mayo: within 3 years of DX (cases = 16)Mayo: within 2 years of DX (cases = 10)
CA19-9 ≥ 550.537 (0.51–0.57)0.559 (0.51–0.62)0.596 (0.51–0.70)
THBS2 − Auto0.552 (0.48–0.64)0.505 (0.46–0.65)0.548 (0.45–0.72)
CA19-9 ≥ 55 + THBS2 − Auto0.585 (0.51–0.67)0.569 (0.50–0.72)0.665 (0.51–0.85)
C
AUCs, combined PLCO and Mayo dataOverall (cases = 216, controls = 615)
CA19-9 ≥ 550.554 (0.54–0.57)
THBS20.529 (0.49–0.56)
CA19-9 ≥ 55 + THBS20.572 (0.53–0.61)
CA19-9 − continuous0.591 (0.55–0.63)
CA19-9 + THBS20.595 (0.56–0.63)
D
AUC (95% CI), combined PLCO and Mayo dataOverall (cases = 216)≤3 years of DX (cases = 80)≤2 years of DX (cases = 54)≤1 year of DX (cases = 29)
CA19-9 ≥ 550.554 (0.54–0.57)0.631 (0.59–0.67)0.679 (0.63–0.73)0.752 (0.68–0.82)
THBS2 − Auto0.529 (0.49–0.56)0.522 (0.47–0.58)0.549 (0.49–0.62)0.539 (0.47–0.62)
CA19-9 ≥ 55 + THBS2 − Auto0.572 (0.53–0.61)0.620 (0.58–0.70)0.699 (0.61–0.76)0.746 (0.67–0.84)
  • A. Area under the curve (AUC) analysis by proximity to diagnosis of CA19-9, THBS2, and the combination of the two over the entire PLCO data set and for samples either 3 or 2 years prior to a PDAC diagnosis. DX, diagnosis. Case numbers as shown, compared with 475 controls.

  • B. AUC analysis by proximity to diagnosis of CA19-9, THBS2, and the combination of the two over the entire Mayo Clinic data set and for samples either 3 or 2 years prior to a PDAC diagnosis. Case numbers as shown, compared with 140 controls.

  • C. AUC analyses of combined PLCO and Mayo Clinic data sets using either our standard 55 U/mL cutoff for CA19-9 levels or CA19-9 levels as a continuous variable.

  • D. AUC analysis by proximity to diagnosis of CA19-9, THBS2, and the combination of the two over the entire combined PLCO and Mayo Clinic data sets and for samples either 3, 2, or 1 year prior to a PDAC diagnosis. Case numbers as shown, compared with a total of 615 controls.